Mike, share price is only HALF the equation. How many shares were outstanding? It's market cap that all should be comparing. However comparisons are of little value for this topic. Diff drugs. Diff spaces. Diff markets. Diff histories. Diff short interest. Diff mkt expectations, etc.
Hey Dean - DNDN hit $55.00 post approval and their RX is $94,000 for each treatment and the market is 3% the size of the prospective market for Afrezza. In addition, consider the Technosphere platform, the cancer RXs and the other IP, all protected with patent shields. This is NOT a $15.00 stock post approval. I'll meet you at the bank.
It indeed was over $10.00 prior to the last PDUFA date and subsequent CRL, so I expect another ramp up. My reason for a conservative estimate post approval is that we just diluted 50% further from 130MM shares at last PDUFA. Still a ton of upside, particularly at this PPS. JMHO.